Fridriksdottir Hafrun Form 3 January 02, 2018

## FORM 3

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

**SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

A Fridriksdottir Hafrun

(Last) (First) (Middle)

Statement

(Month/Day/Year)

01/01/2018

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol

TEVA PHARMACEUTICAL INDUSTRIES LTD

[TEVA]

4. Relationship of Reporting

Person(s) to Issuer

5. If Amendment, Date Original

Filed(Month/Day/Year)

C/O TEVA

**PHARMACEUTICAL** 

INDUSTRIES LTD., Â 5 BASEL

STREET

(Street)

(Check all applicable)

(give title below) (specify below)

Executive VP, Global R&D

Director 10% Owner X\_ Officer Other

6. Individual or Joint/Group

Filing(Check Applicable Line) \_X\_ Form filed by One Reporting

Person

Form filed by More than One

Reporting Person

## **PETACH** TIKVA, L3Â 4951033

1. Title of Security

(Instr. 4)

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

Ownership Form:

4. Nature of Indirect Beneficial Ownership (Instr. 5)

Direct (D) or Indirect

(I) (Instr. 5)

Ordinary Shares (1)

3,346

Â D

Reminder: Report on a separate line for each class of securities beneficially

owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and **Expiration Date** (Month/Day/Year)

3. Title and Amount of Securities Underlying **Derivative Security** 

4. 5. Conversion Ownership Form of

6. Nature of Indirect Beneficial Ownership

or Exercise (Instr. 5)

## Edgar Filing: Fridriksdottir Hafrun - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
Stock Options (right to buy)	(2)	06/30/2024	Ordinary Shares (1)	22,809	\$ 48.69	D	Â
Stock Options (right to buy)	(3)	08/01/2026	Ordinary Shares (1)	15,990	\$ 52.96	D	Â
Stock Options (right to buy)	(4)	09/08/2026	Ordinary Shares (1)	5,553	\$ 50.21	D	Â
Stock Options (right to buy)	(5)	11/30/2026	Ordinary Shares (1)	57,167	\$ 37.7	D	Â
Stock Options (right to buy)	(6)	02/14/2027	Ordinary Shares (1)	85,042	\$ 34.9	D	Â
Restricted Share Units	(7)	(7)	Ordinary Shares (1)	3,432	\$ (8)	D	Â
Restricted Share Units	(9)	(9)	Ordinary Shares (1)	9,280	\$ (8)	D	Â
Restricted Share Units	(10)	(10)	Ordinary Shares (1)	2,330	\$ <u>(8)</u>	D	Â
Restricted Share Units	(11)	(11)	Ordinary Shares (1)	2,242	\$ (8)	D	Â
Restricted Share Units	(12)	(12)	Ordinary Shares (1)	796	\$ (8)	D	Â
Restricted Share Units	(13)	(13)	Ordinary Shares (1)	10,844	\$ <u>(8)</u>	D	Â
Restricted Share Units	(14)	(14)	Ordinary Shares (1)	16,061	\$ (8)	D	Â

# **Reporting Owners**

Reporting Owner Name / Address		Relationships					
		10% Owner	Officer	Other			
Fridriksdottir Hafrun C/O TEVA PHARMACEUTICAL INDUSTRIES LTD. 5 BASEL STREET PETACH TIKVA, L3 4951033	Â	Â	Executive VP, Global R&D	Â			
Signatures							

/s/ Dov Bergwerk, as attorney-in-fact for Hafrun 01/02/2018 Fridriksdottir

> \*\*Signature of Reporting Person Date

Reporting Owners 2

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- (2) Stock options were granted on July 1, 2014, with 7,603 having vested on July 1, 2017 and 7,603 vesting on each of July 1, 2018 and July 1, 2019.
- (3) Stock options were granted on August 2, 2016, with 3,997 having vested on August 2, 2017, 3,997 vesting on each of March 17, 2018 and March 17, 2019 and 3,999 vesting on March 17, 2020.
- (4) Stock options were granted on September 9, 2016, with 1,388 having vested on September 9, 2017, 1,388 vesting on each of March 17, 2018 and March 17, 2019 and 1,389 vesting on March 17, 2020.
- (5) Stock options were granted on November 30, 2016, with 14,292 vesting on November 30, 2018 and 42,875 vesting on November 30, 2019.
- (6) Stock options were granted on February 14, 2017, with 28,347 vesting on each of February 14, 2019 and February 14, 2020 and 28,348 vesting on February 14, 2021.
- (7) Restricted share units were granted on May 8, 2014 and vest on March 5, 2018.
- (8) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- (9) Restricted share units were granted on July 1, 2014, with 4,640 vesting on each of December 31, 2018 and December 31, 2019.
- (10) Restricted share units were granted on March 4, 2015, with 1,165 vesting on each of March 4, 2018 and March 4, 2019.
- (11) Restricted share units were granted on August 2, 2016, with 747 vesting on each of March 17, 2018 and March 17, 2019 and 748 vesting on March 17, 2020.
- (12) Restricted share units were granted on September 9, 2016, with 265 vesting on each of March 17, 2018 and March 17, 2019 and 266 vesting on March 17, 2020.
- (13) Restricted share units were granted on November 30, 2016, with 2,711 vesting on November 30, 2018 and 8,133 vesting on November 30, 2019.
- (14) Restricted share units were granted on February 14, 2017, with 5,353 vesting on each of February 14, 2019 and February 14, 2020 and 5,355 vesting on February 14, 2021.

Â

### Remarks:

The Reporting Person is filing this form in connection with the Issuer's transition from a foreign p

### Exhibit List

## Â Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.